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ditorialhe  prescription  of  oral  anticancer  drugs:  Another
erspective recent editorial in this journal argued against restricting the
ight of non-medical oncologists to prescribe oral anticancer
rugs.1 As representatives of the Latin American Association
f Radiation Oncology (ALATRO), we fully support the posi-
ion expressed by the Spanish Society of Radiation Oncologists
SEOR) in that editorial. We believe the outcome of this ongo-
ng debate in Europe2,3 has the potential to shape the future
f cancer care around the world. For these reasons, we feel
ompelled to make our own views of this issue known.
Some—though we  presume not all—medical oncologists
elieve that only they should control the prescription of oral
ancer medications. However, most other cancer care special-
sts strongly disagree.4,5 The authors of the aforementioned
ditorial argue that the campaign being carried out by medical
ncologists is largely a defensive manoeuvre. The diminish-
ng use of intravenously delivered anti-cancer drugs—long the
omain of medical oncology—coupled with the rise of newer,
rally administered drugs and targeted molecular agents,
ould pose a threat to the very existence of the speciality of
edical oncology. This threat may be real, but we  believe that
uch an aggressive response to this perceived danger is mis-
uided. The ﬁeld of oncology needs greater collaboration, not
ess.
Radiotherapy is increasingly used in combination—either
djuvantly or concurrently—with chemotherapy and it is not
ossible to separate the two. What would happen to our
peciality if we  were no longer able to prescribe the radiosen-
itizing and radio-potentiating oral drugs used in most current
adiochemotherapy regimens?6–8 The clear message we  wish
o send to our colleagues in medical oncology is that aggres-
ive tactics to preserve their speciality are neither constructive
or necessary. In our opinion, the world will not end if several
ifferent, but related, specialities continue to maintain their
ong-established practice of prescribing oral cancer drugs.
The complex nature of cancer care requires the inter-
ention of numerous specialists. While great strides have
een made in recent years towards greater collaboration,
ome resistance to the multidisciplinary approach to can-
er care still remains. This less-than-complete willingness to
oin in a fully collaborative approach to care is problematic.However, this is not the only impediment to developing a
stronger multidisciplinary model: another obstacle is the lack
of clearly deﬁned roles. Many of the functions of cancer care
specialists can—and do—overlap, and while this is not a major
problem, it can sometimes cause confusion with regards to the
responsibilities of each specialist.
In this editorial, we wish to make two important points.
First of all, a greater effort needs to be made to promote an
authentic multidisciplinary approach to cancer care, in which
specialists fully embrace the spirit of positive collaboration
and teamwork. We  believe that we should view each other
as colleagues, not competitors. Secondly—and this point is
closely related to the ﬁrst—we believe that the roles of the var-
ious cancer care specialists need to be more  precisely deﬁned,
so that our individual responsibilities are clear.
1.  The  need  to  strengthen  the
multidisciplinary  approach
Medical care has become increasingly specialised in recent
years, and oncology is no exception. Cancer is a complex,
multifactorial disease with diverse treatment options and
advances in our understanding of this disease and in new
treatments (e.g., robotic surgery, radiosurgery, drugs, genet-
ics, and advanced radiotherapy techniques) mean that input
from diverse specialists with unique knowledge is increas-
ingly necessary. The response to this increasing complexity
has been the widespread adoption of the multidisciplinary
approach.9,10
From the perspective of the radiation oncologist, the need
for a multidisciplinary approach to cancer is obvious.11,12 In
many  countries our specialty relies almost entirely on referrals
from other professionals, and for this reason radiation oncol-
ogy has a long tradition of good communication with other
physicians. Moreover, because radiotherapy can be either a
primary or adjuvant treatment, specialists is this ﬁeld are
accustomed to collaborating closely with other specialists.
Several approaches could be taken to increase collabora-
tion. For example, the multidisciplinary approach to cancer
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should be the standard model of care taught to medical stu-
dents and residents. In addition, countries that have yet to
adopt this model, which includes interdisciplinary tumour
boards and treatment units, should be encouraged to do so.
Much  of these efforts need to come from the top through
closer collaboration among the relevant medical societies who
must work together to improve the model and to resolve any
conﬂicts.
2.  The  need  to  better  deﬁne  the  role  of
cancer  care  specialists:  the  case  of  Radiation
Oncology
Some of the controversy surrounding proposals to limit the
right to prescribe oral drugs arise from confusion about the
role of the various specialities in a comprehensive cancer
care model. It sometimes seems that the role of the radiation
oncologist is misunderstood, even within the ﬁeld of oncology.
We are not simply technicians skilled at delivering radiation
to the tumour site; rather we  are clinical oncologists with a
strong background in medicine that includes training in inter-
nal medicine. We  are not RADIATION oncologists, but rather
radiation ONCOLOGISTS, as Zietman so astutely observed.13
Let us consider the historical perspective. Radiation itself
has been used as a cancer treatment practically from its
discovery at the end of the 19th century.14 In addition, Radio-
therapy was the ﬁrst oncological specialty to be recognized (in
1922, at the Congress of Oncology in Paris).15 The academic
ﬁeld of radiation oncology grew out of radiology, as a distinc-
tion was made between radiation for imaging and therapeutic
radiation. This separation from radiology occurred only 30–40
years ago, and radiation oncology as a medical specialty is
still a relatively young ﬁeld. In fact, for decades the only truly
effective cancer treatments available were surgery and radio-
therapy. As a result, from its very beginning, the practice of
radiation oncology was eminently clinical and the role of the
radiation oncologist extended from the moment of diagnosis
through terminal care. When it was discovered that certain
chemotherapeutic agents potentiate the effects of radiothe-
rapy, these new agents were administered in combination
with radiotherapy. Logically, it was the radiation oncologist
who  was responsible for managing the administration of these
agents. Indeed, in many  parts of the world (e.g., the United
Kingdom) the same physician, called a “clinical oncologist”,
is still responsible for the non-surgical treatment of cancer,
and prescribes chemotherapy as well as radiotherapy. This
is important since having only one specialist in charge of
treatment reduces costs and, most importantly, saves time
between diagnosis and initiation of treatment.
Regardless of whether we are known as clinical or radia-
tion oncologists, our main function continues to be clinical. As
clinicians, we  require a strong foundation in general medicine,
including a solid understanding of the histology and pathol-
ogy of cancer. Not only must the radiation oncologist be
skilled at performing physical examinations and in inter-
preting diagnostic and planning images, but he/she must
know how to combine all of this information into planning
the appropriate treatment. Fortunately, we are well-prepared
for clinical work by our medical education and rotationsiotherapy 1 7 ( 2 0 1 2 ) 295–297
in relevant specialities—including internal medicine—during
residency. A large part of our speciality involves the study and
understanding of radiobiology because it is essential that we
understand the impact of both older drugs and more  modern
targeted therapies on tissues, particularly in conjunction with
radiotherapy.
Our speciality has, without a doubt, a large technical com-
ponent. Perhaps for this reason, non-oncologists sometimes
associate us with the high-tech tools of our trade: linear accel-
erators and other advanced machines. However, what they fail
to see is the large clinical component of our work involving
patient care from diagnosis to long-term follow-up. Clearly,
we have an obligation not only to keep abreast of the lat-
est technologies, but also the latest advances in molecular
and systemic therapies. This all requires constant effort on
our part, and for this reason we have learned to delegate to
other professionals (medical physicists, and radiation oncol-
ogy nurses and technologists). Our focus is and will continue
to be on the clinical aspects of our specialty. In this sense,
we believe that there are some parallels with surgical oncol-
ogy: the practice of surgery is not mutually exclusive with the
practice of medicine, and the same is true for radiotherapy.
3.  Conclusion
As we have argued in this editorial, attempts to restrict the
prescription of oral drugs to medical oncologists are simply
ill-advised. Medical and radiotherapeutic treatment of cancer
are virtually inseparable these days, and in most cases, clinical
guidelines indicate concomitant radiochemotherapy.
Let us be clear. In this complex ﬁeld of oncology, we  strongly
believe that it is essential that all specialists work together as a
team to deliver the best patient care. We also believe that this
model will work only if all participants believe in the value of
the model and in each other. We must always keep foremost
in our minds that regardless of our specialty, we  are all physi-
cians, and our primary responsibility is the well-being of the
patient, not the survival or predominance of our specialty.
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